Policy and Advocacy

Advanced Integrative Medical Science (AIMS) Institute is a Seattle-based clinic led by Dr. Sunil Aggarwal offering ketamine-assisted psychotherapy, entheogen-assisted therapy, integrative oncology, and palliative care. The institute is notable for a landmark DEA lawsuit seeking right-to-try psilocybin access for patients with serious illness, placing it at the forefront of psychedelic medicine advocacy and clinical practice in the US.

Alberta Health Services (AHS) is Canada's largest provincial health authority, responsible for delivering healthcare across Alberta and supporting clinical research including in emerging fields like psychedelic-assisted therapy. AHS played a central role in Alberta becoming the first Canadian province to regulate psychedelic-assisted therapy, with its addiction medicine team supporting early access programs and clinical trial infrastructure for psilocybin and MDMA studies.

The American Academy of Child and Adolescent Psychiatry (AACAP) is a major US professional medical association representing child and adolescent psychiatrists and publisher of the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP). The organization and its journal have actively engaged with questions around psychedelic-assisted therapy for youth, publishing clinical research and ethical analyses on the potential use of psilocybin and MDMA in adolescent populations.

The American Psychiatric Association (APA) is the world's largest psychiatric professional association with over 37,000 physician members, and publisher of the American Journal of Psychiatry and the DSM diagnostic standards. In 2022 the APA issued a landmark position statement on psychedelics, acknowledging promising early evidence for psilocybin and MDMA-assisted therapy while calling for rigorous research and caution against clinical use outside approved investigational settings.

The Arizona Biomedical Research Commission (ABRC) is a state government body within the Arizona Department of Health Services that funds biomedical research, having become the first state agency in the US to direct $5 million toward randomized controlled clinical trials of psilocybin whole mushrooms for conditions including PTSD, depression, and addiction. The ABRC oversees the Arizona Psilocybin Research Advisory Council and has since expanded its psychedelic research portfolio to include an additional $5 million for ibogaine clinical trials.

AstraZeneca is a British-Swedish multinational biopharmaceutical company developing medicines across oncology, cardiovascular, respiratory, and neurological areas, with psychiatric products that intersect with psychedelic research contexts. AstraZeneca's antidepressants and psychiatric medications have featured as active comparators in landmark psychedelic clinical trials, including the influential psilocybin vs. escitalopram depression study at Imperial College London.

Australia became the world's first nation to reschedule psilocybin and MDMA as Schedule 8 controlled medicines in February 2023, permitting authorised psychiatrists to prescribe psilocybin for treatment-resistant depression and MDMA for PTSD effective July 2023. The Therapeutic Goods Administration (TGA) leads the regulatory framework for these therapies under a tightly supervised Authorised Prescriber scheme.

Beijing Medical Award Foundation (北京医学奖励基金会) is a Beijing-based public charity established in 2002 in Xicheng District, dedicated to enhancing medical standards through professional incentives, grants, and awards recognising biomedical research achievement. The foundation provides funding and recognition supporting clinical and scientific excellence in Chinese medicine, including psychiatry and neuroscience fields.

Berry Consultants is a US statistical consulting firm specializing in Bayesian adaptive clinical trial design, with expertise in platform trials and adaptive dose-finding studies increasingly applied in psychedelic and psychiatric drug development. The firm has engaged with regulatory frameworks for psychedelic medicines, including commenting on FDA guidance for clinical trials involving psilocybin and MDMA.

The California HIV/AIDS Research Program (CHRP) is a state-funded grant-making program administered by the University of California Office of the President that has supported over three decades of high-risk, high-reward HIV research in California, including mental health comorbidities in people living with HIV. CHRP has funded research that intersects with psychedelic medicine, including studies on psychological distress in AIDS survivors treated with psilocybin by California-based researchers.

US-based nonprofit institute founded by Brazilian anthropologist Dr. Bia Labate that bridges psychedelic plant medicine traditions and emerging clinical science, producing research and accessible cultural commentary on ayahuasca, psilocybin, and other plant medicines while centering Indigenous reciprocity, racial equity, and social justice. Chacruna hosts annual interdisciplinary conferences since 2018, operates a Racial Equity and Access Committee, and amplifies voices of Indigenous peoples, women, queer communities, and the Global South in psychedelic science and policy.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.

Non-profit founded in 2009 and headquartered in Barcelona, dedicated to transforming society's relationship with psychoactive plants including ayahuasca, iboga, and cannabis. ICEERS combines scientific research, legal advocacy, harm reduction services, and ethnobotanical education — including conducting the world's first ibogaine clinical trial for opioid dependency.

Long Alliantie Nederland (Lung Alliance Netherlands) is the Dutch national patient alliance representing people with lung diseases including COPD, asthma, and pulmonary fibrosis; as one of 19 consortium partners in the EU Horizon Europe–funded PsyPal trial (€6.5M), the Alliance contributes patient expertise for the COPD arm investigating psilocybin therapy for psychological distress in palliative care.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

Psychedelic Coalition for Health (PCH) is a clinician-led psychedelic medicine education and advocacy organization co-founded by psychotherapists Lauren Taus and Nicholas Brüss, offering psychedelic-assisted therapy training, virtual symposia, and scholarship programs for healthcare professionals. PCH trains licensed clinicians in ketamine, MDMA, and IFS-informed approaches while advocating for equitable access to and responsible implementation of psychedelic medicine.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit founded by the late Dr. Parth Gandhi to advance psychedelic-assisted therapy through education, research, and advocacy in the Intermountain West. SCPTR organizes the annual Intermountain Psychedelic Symposium and supports practitioners, researchers, and policy reform in the region.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

atai Life Sciences (operating as atai Therapeutics, Inc. in the US) is a publicly traded clinical-stage biopharmaceutical company founded in 2018 with the largest and most diverse portfolio of psychedelic-derived drug candidates, including DMT, R-MDMA, psilocin, 5-MeO-DMT (BPL-003), and ibogaine for depression, anxiety, and addiction. Following its 2024 merger with Beckley Psytech to form AtaiBeckley, BPL-003 received FDA Breakthrough Therapy designation for treatment-resistant depression with Phase 3 trials anticipated in 2026.